Az St-Jan Brugge-Oostende A.V.

Bruges 8000

0 studies enrolling now · 13 studies all time

What they study most

Acute Myeloid Leukemia, Alzheimer Disease, Anemia, Chronic Heart Failure With Preserved Ejection Fraction, Chronic Lymphocytic Leukemia, Cognitive Dysfunction, Dementia, Heart Failure, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Relapsed and/or Refractory Multiple Myeloma

Studies at this site

• A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma — Running, not enrolling
• A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy — Running, not enrolling
• Phase 1-2 Study of Low Dose ASTX727 (ASTX727 LD) in Lower Risk MDS — Completed
• A Study of JNJ-63733657 in Participants With Early Alzheimer's Disease — Stopped early
• A Study of JNJ-64264681 and JNJ-67856633 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia — Completed
• Rituximab Plus Lenalidomide for Patients With Relapsed / Refractory Indolent Non-Hodgkin's Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma) — Completed
• A Study to Determine the Safety and Efficacy for the Combination of Durvalumab and Daratumumab in Relapsed and Refractory Multiple Myeloma — Stopped early
• A Study of Ixazomib, Given With Dexamethasone in Adults With Multiple Myeloma — Completed
• Patient-reported Outcomes in Vericiguat-treated Patients With HFpEF — Completed
• Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple Myeloma — Completed
• A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Lower Risk Myelodysplastic Syndrome (MDS) Without Del 5q — Completed
• A Trial to Study Neladenoson Bialanate Over 20 Weeks in Patients With Chronic Heart Failure With Reduced Ejection Fraction — Completed
• Study of Vosaroxin or Placebo in Combination With Cytarabine in Patients With First Relapsed or Refractory AML — Completed